The drug in the auto injector is probably Versed/Midazolam, the big and very potent big sister of diazepam. The following indicates that NIH and other heavies in medicine are preferring Versed/Midazolam as the im drug of choice for stopping seizures.
For release: Wednesday, February 15, 2012
NIH study finds method safe and effective for paramedics
Drug delivery into muscle using an autoinjector, akin to the EpiPen used to treat serious allergic reactions, is faster and may be a more effective way to stop status epilepticus, a prolonged seizure lasting longer than five minutes, according to a study sponsored by the National Institutes of Health. Status epilepticus is a potentially life-threatening emergency that causes 55,000 deaths each year. Anticonvulsant drugs are typically delivered intravenously (IV) as a first-line treatment.
The NIH RAMPART study compared the safety and effectiveness of two methods for treating status epilepticus.
Starting an IV in a patient experiencing seizures can pose a challenge for paramedics and waste precious time. Giving an intramuscular shot is easier, faster, and more reliable, especially in patients having convulsions. The researchers sought to determine whether an intramuscular injection, which quickly delivers anticonvulsant medicine into a patient’s thigh muscle, is as safe and effective as giving medicine directly into a vein. The study, which was carried out by paramedics, compared how well delivery by each method stopped patients’ seizures by the time the ambulance arrived at the emergency department.
The investigators compared two medicines known to be effective in controlling seizures, midazolam and lorazepam. Both are benzodiazepines, a class of sedating anticonvulsant drugs. Midazolam was a candidate for injection because it is rapidly absorbed from muscle. But lorazepam must be given by IV. The study found that 73 percent of patients in the group receiving midazolam were seizure-free upon arrival at the hospital, compared to 63 percent of patients who received IV treatment with lorazepam. Patients treated with midazolam were also less likely to require hospitalization than those receiving IV lorazepam. Among those admitted, both groups had similarly low rates of recurrent seizures. The study appears in the Feb. 16, 2012 issue of The New England Journal of Medicine.*
“Patients with status epilepticus can suffer severe consequences if seizures are not stopped quickly. This study establishes that rapid intramuscular injection of an anticonvulsant drug is safe and effective,” said Walter Koroshetz, M.D., deputy director of the National Institute of Neurological Disorders and Stroke (NINDS), part of the NIH, which funded the study.
Autoinjector used in RAMPART
The investigators said that while autoinjectors might someday be available for use by epilepsy patients and their family members, more research is required. Because of the strong sedative effect of midazolam, on-site medical supervision is now required for the safety of the patient.
The Rapid Anticonvulsant Medication Prior to Arrival Trial (RAMPART) study was conducted through the NINDS’ Neurological Emergencies Treatment Trials (NETT) network. Additional funding was provided by the NIH Countermeasures Against Chemical Threats (NIH CounterACT) program and the Biomedical Advanced Research and Development Authority (BARDA). The Department of Defense’s Chemical Biological Medical Systems (CBMS) Joint Project Management Office provided the autoinjectors for the trial under a Memorandum of Agreement with NINDS.
NIH CounterACT, BARDA and CBMS are responsible for enhancing the U.S. government’s development of medical countermeasures to natural and intentional public health threats. (Please see full statement below on CBMS). The chemical defense community has a longstanding interest in research on the rapid treatment of nerve agent-induced seizures. As the RAMPART study was being planned, investigators learned that the departments of Defense and Health and Human Services were already working with a midazolam autoinjector and the study was an opportunity to confirm its effectiveness in patients with seizures.
“There was great synergy when we realized that RAMPART was studying a similar problem that was of concern to the chemical defense community. This led to a perfect collaboration between HHS and DoD,” said David Jett, Ph.D., program director for NIH CounterACT and NINDS. “The broader implication of RAMPART is that we now have critical information from studies in humans that a safe and effective tool may one day be available to enhance our public health preparedness. Auto injectors provide a highly practical way to treat hundreds of people quickly during an emergency.”
RAMPART is the first randomized clinical trial to investigate whether intramuscular delivery of midazolam is as effective as IV lorazepam, the current standard of care therapy. The trial started in 2009 and completed enrollment in June, 2011. RAMPART involved more than 79 hospitals, 33 emergency medical services agencies, more than 4,000 paramedics and 893 patients ranging in age from several months old to 103. The network of investigators that designed and carried out the trial was established by NINDS to conduct clinical trials on a variety of acute conditions affecting the brain such as stroke and traumatic brain injury. NETT investigators are organized into a system of 17 major research hospitals each of which is linked to several community hospitals and other medical centers.
Another special aspect of the study was that it was conducted under exception from informed consent for emergency research. This is a federal regulation to protect patients who are involved in research when consent is not possible because of their medical condition. Community consultation is held in advance of the study to raise awareness, ensure transparency, and get input from local residents.
Paramedics in RAMPART used study boxes with a time-stamped voice recorder, designed by the NETT team. This tool allowed paramedics to make quick decisions, indicate the time treatment began and the time the patient’s convulsions stopped, all without having to interrupt patient care to record data. The goal of the study was to control the seizures within 10 minutes without having to deliver a second dose of medicine. Prolonged status epilepticus can last for hours and sometimes is controlled only with general anesthesia.
“Few other areas of medicine are as time-dependent as injury to the brain. In epilepsy, even a few minutes can be important. With every minute the seizure continues, it becomes harder to stop. RAMPART offers first responders an important treatment tool that will have a meaningful impact on the lives of many people with epilepsy,” said Robert Silbergleit, M.D., of the University of Michigan in Ann Arbor, first author of the NEJM paper.
*Silbergleit, R et al. Intramuscular versus Intravenous Therapy for Prehospital Status Epilepticus. New England Journal of Medicine, February 16, 2012.
A little birdie told me that this is his long-range diagnosis.
http://www.epilepsy.com/article/2013/6/do-you-know-what-jacksonian-march
Do you know what a Jacksonian March is?
Wednesday, June 19, 2013
Q: What is a “Jacksonian” seizure?
A. Jacksonian march, also called Jacksonian seizure, is one kind of a simple partial seizure. “Simple” in this context means patients do not lose awareness. Partial means that abnormal neuron firing only occurs in part of the brain, and, accordingly, abnormal movement or sensation is limited to only part of the body. The characteristic features of Jacksonian march are (1) it only occurs on one side of the body; (2) it progresses in a predictable pattern from twitching or a tingling sensation or weakness in a finger, a big toe or the corner of the mouth, thenmarches over a few seconds to the entire hand, foot or facial muscles.
Q: Is it a new seizure type?
A: No, it is not. It is a subtype of partial seizures. It was described in 1870 by John Hughling Jackson, an English neurologist. Jackson considered that parts of the body were represented in discrete parts of the nervous system including both sensory and motor systems. His theory was later confirmed by other neurologists by demonstrating the electrical excitability in a certain part of dog’s brain, the area called motor cortex. Interestingly, Jackson’s wife Elizabeth Dade Jackson had Jacksonian focal seizure before she died of cerebral venous thrombosis in 1876.
Q: What are other features in Jacksonian march?
A: Jacksonian march seizures are generally brief and relatively mild. They are episodic, come and go. There is no confusion afterwards. Sometimes patients may not even notice them. Some patients may also have a phenomenon called “automatism,” such as compulsively licking the lips, fumbling with clothing, or other rhythmic finger movements. Others may experience head turning, eye movement, muscle cramping, numbness, tingling, and a crawling sensation over the skin. Hallucinations can occur too, which can be visual or auditory, meaning patients may see or hear things that are not there.
Q: If someone has symptoms as you just mentioned, are we sure he/she has Jacksonian seizure?
A: No, we cannot be sure because there are diseases that can mimic Jacksonian seizures. For example, migraine can also have hemibody weakness or sensation changes. Patients with stroke can have one side of body weakness or numbness/tingling as well. There is a particular type called capsular warning syndrome in which patients can present with the same symptoms as patients with Jacksonian march seizures, such as short stereotyped episodes of tingling/numbness ascending from the foot to the hand on one side of body.
Q: So how can we distinguish Jacksonian march from its mimics?
A: This can be done by a good description of the symptoms, electroencephalogram (EEG), and brain imaging like magnetic resonance imaging (MRI). EEG-video monitoring can also be helpful in diagnosis.
Q: How do we treat Jacksonian march?
A: In themselves they may not require antiseizure medications since the symptoms are so mild and brief. However, most patients with Jacksonian seizures also have more severe seizures, including full convulsions. Also the seizures may be the manifestations of an underlying cause that may itself require treatment, such as a tumor.
Q: Any other advice to people who are concerned about Jacksonian seizures?
A: Jackson seizures are a type of seizures seen in patients with focal (localized) epilepsy. Talk to your neurologist or epileptologist about your symptoms. Obtain a clear diagnosis and talk with your neurologist or epileptologist about appropriate management plan.
Authored by: Selim R. Benbadis MD | Curtis Keller MD | Lingling Rong MD on 6/2013